Glenmark’s Ryaltris nasal spray gets approval in Europe for treatment of allergic rhinitis
It is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for the treatment of symptoms…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Glenmark and Bausch Health join together to commercialise RYALTRIS nasal spray in Canada
Glenmark Pharmaceuticals and Bausch Health Companies have entered into an exclusive licensing agreement for the commercialisation…
Glenmark, Bausch Health partner to commercialise RYALTRIS nasal spray in Canada
RYALTRIS is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in…
Govt of India gives ‘India Pharma Innovation of the Year’ Award to Glenmark
The Award recognises Glenmark’s patents and commercialised innovations over the last three years
Glenmark launches Remogliflozin + Vildagliptin FDC in India to treat Type 2 diabetes
The FDC will be marketed under two brand names, Remo V and Remozen V, priced at Rs 14 per tab and Rs 28 per day cost of therapy
Glenmark Pharma gets ANDA tentative approval for Dabigatran Etexilate Capsules
It is the generic version of Pradaxa Capsules, 75 mg, 110 mg, and 150 mg, of Boehringer Ingelheim
Dr Reddy’s to acquire select anti-allergy brands from Glenmark in Russia and other CIS countries
The acquired brands represent two types of products, mometasone mono product and combination of mometasone with azelastine.
Glenmark appoints Dipankar Bhattacharjee to its Board of Directors
Bhattacharjee was previously President & CEO – Global Generic Medicines of Teva Pharmaceutical Industries
Glenmark to launch FabiFlu (400 mg) for COVID-19 treatment
With the new 400 mg version, patients need to consume nine tablets on Day 1, and thereafter two tablets twice a day from Day 2…
DCGI queries pharma company on its claim of FabiFlu use for COVID-19 patients with comorbidities
As per statement by the Glenmark and media reports, the DCGI had accelerated the process for clinical trials and reviews…